Tokai Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Tokai Pharmaceuticals's estimated annual revenue is currently $5.1M per year.
- Tokai Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Tokai Pharmaceuticals has 33 Employees.
- Tokai Pharmaceuticals grew their employee count by 14% last year.
Tokai Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Technical Operations | Reveal Email/Phone |
2 | VP, Biometrics | Reveal Email/Phone |
3 | President and Chief Scientific Officer | Reveal Email/Phone |
4 | General Counsel, Chief Compliance Officer, & Corporate Secretary | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Director Project Management | Reveal Email/Phone |
7 | Chief Regulatory Officer | Reveal Email/Phone |
8 | Senior Clinical Project Manager | Reveal Email/Phone |
9 | Project Manager Contract | Reveal Email/Phone |
10 | Clinical Project Manager | Reveal Email/Phone |
Tokai Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Tokai Pharmaceuticals?
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
keywords:N/AN/A
Total Funding
33
Number of Employees
$5.1M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tokai Pharmaceuticals News
Honoraria: Research to Practice, Astellas Pharma, AstraZeneca, ... Janssen Oncology, Tokai Pharmaceuticals, Astellas Pharma, Incyte, Pfizer,...
Honoraria: Research to Practice, Astellas Pharma, AstraZeneca, ... Janssen Oncology, Tokai Pharmaceuticals, Astellas Pharma, Incyte, Pfizer,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.8M | 33 | 6% | N/A |
#2 | $5.1M | 33 | 3% | N/A |
#3 | $5.1M | 33 | 14% | N/A |
#4 | $3.8M | 33 | -8% | N/A |
#5 | $5.8M | 33 | -6% | N/A |